Objective:

The article examines the objective, findings, and clinical context described in Video: The Ultimate in Translational Medicine – with Harold Keer.

Approach:

• Career perspective: Keer describes industry as a way to scale discoveries into medicines for patients, which he calls “the ultimate translational medicine.”
• Changing treatment landscape: He reflects on the expansion from cytotoxic chemotherapy to targeted therapies, monoclonal antibodies, immunotherapies, bispecific antibodies, and antibody-drug conjugates.
• Ongoing challenges: The interview addresses why promising cancer programs fail, the potential and possible “irrational exuberance” around emerging modalities, and the need to keep patients central to clinical development.

Key Findings:

• Keer identifies destroying malignant cells while sparing healthy tissue as a fundamental challenge.
• He notes that targets once considered undruggable, including RAS, have become active areas of development.
• Keer describes helping advance Taiho’s acquired ADC technology into clinical development as unfinished work.

Interpretation:

The interview presents Keer’s view that translating discoveries into medicines at scale is a defining opportunity of industry-based medicine development.

Limitations:

• The supplied context is a brief description of an interview and does not provide detailed evidence, methods, or specific study results.

Sources:

• Article context supplied by the user